|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Steady-state pharmacokinetics and pharmacodynamics of piperacillin/tazobactam administered by prolonged infusion in hospitalised patients显示文摘 | Katherine M. Shea S. Christian Cheatham Matthew F. Wack David W. Smith Kevin M. Sowinski Michael B. Kays | 2009 | International Journal of Antimicrobial Agents2009，，5： | 1 |
| 2 | Endocardial and Epicardial Derived FGF Signals Regulate Myocardial Proliferation and Differentiation In Vivo显示文摘 | Kory J. Lavine Kai Yu Andrew C. White Xiuqin Zhang Craig Smith Juha Partanen David M. Ornitz | 2005 | Developmental Cell2005，，： | 1 |
| 3 | Celecoxib, a Selective Cyclooxygenase-2 Inhibitor, Decreases Monocyte Chemoattractant Protein-1 Expression and Neointimal Hyperplasia in the Rabbit Atherosclerotic Balloon Injury Model显示文摘 | Kai Wang Khaldoun Tarakji Zhongmin Zhou Ming Zhang Farhad Forudi Xiaorong Zhou Alane T. Koki Mark E. Smith Bradley T. Keller Eric J. Topol A. Michael Lincoff Marc S. Penn | 2005 | Journal of Cardiovascular Pharmacology2005，，1： | 1 |
| 4 | Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients显示文摘 | Cheatham SC Kays MB Smith DW | 2008 | Pharmacotherapy2008，28，6： | 1 |
| 5 | Direct detection and measurement of wall shear stress using a filamentous bio-nanoparticle显示文摘墙砍动人的液体在表面上施加的应力(WSS ) 关于脉管的功能包括那些影响许多过程。WSS 在正常生理学起一个重要作用(例如 angiogenesis ) 并且影响微脉管系统分子的运输的主要功能。波动的 WSS 的点在很多疾病显示出畸形;然而,为在生理的系统直接测量 WSS 没有确定的技术。所有当前的方法依靠大批从测量速度坡度获得的估计流动数据。在这个工作,我们报导能直接与亚微米在 microfluidic 房间测量 WSS 的 nanosensor 由使用病毒的一种特定的类型的空间分辨率,抗菌素 M13,它荧光灯地被标记并且抛锚到表面。nanosensor 能为生物织物被校准并且适应,这被表明,揭示 WSS 在不能从体积流动大小精确地计算的房间微域。这个方法在生物学和 microfluidics 把自己借给对许多应用程序适用的一个平台。 | Daniela P. Lobo Alan M. Wemyss David J. Smith Anne Straube Kai B. Betteridge Andrew H. J. Salmon Rebecca R. Foster Hesham E. Elhegni Simon C. Satchell Haydn A. Little Raul Pacheco-Gomez Mark J. Simmons Matthew R. Hicks David O. Bates Alison Rodger Timothy R. Dafforn Kenton P. Arkill | 2015 | Nano Research2015，8，10： | 1 |
| 6 | A role for C-C chemokines in fibrotic lung disease显示文摘 | Smith RE Strieter RM Kai Zhang | 1995 | Leukoc Biol1995，57，： | 1 |
| 7 | Anti-steatotic and anti-fibrotic effects of the KCa3.1 channel inhibitor, Senicapoc, in non-alcoholic liver disease显示文摘AIM To evaluate a calcium activated potassium channel(KCa3.1) inhibitor attenuates liver disease in models of non-alcoholic fatty liver disease(NAFLD).METHODS We have performed a series of in vitro and in vivo studies using the KCa3.1 channel inhibitor, Senicapoc. Efficacy studies of Senicapoc were conducted in toxin-, thioacetamide(TAA) and high fat diet(HFD)-induced models of liver fibrosis in rats. Efficacy and pharmacodynamic effects of Senicapoc was determined through biomarkers of apoptosis, inflammation, steatosis and fibrosis. RESULTS Upregulation of KCa3.1 expression was recorded in TAA-induced and high fat diet-induced liver disease. Treatment with Senicapoc decreased palmitic aciddriven Hep G2 cell death.(P < 0.05 vs control) supporting the finding that Senicapoc reduces lipiddriven apoptosis in Hep G2 cell cultures. In animals fed a HFD for 6 wk, co-treatment with Senicapoc,(1) reduced non-alcoholic fatty liver disease(NAFLD) activity score(NAS)(0-8 scale),(2) decreased steatosis and(3) decreased hepatic lipid content(Oil Red O, P < 0.05 vs vehicle). Randomization of TAA animals and HFD fed animals to Senicapoc was associated with a decrease in liver fibrosis as evidenced by hydroxyproline and Masson's trichrome staining(P < 0.05 vs vehicle). These results demonstrated that Senicapoc mitigates both steatosis and fibrosis in liver fibrosis models.CONCLUSION These data suggest that Senicapoc interrupts more than one node in progressive fatty liver disease by its anti-steatotic and anti-fibrotic activities, serving as a double-edged therapeutic sword. | latha paka david e smith dawoon jung siobhan mccormack ping zhou bin duan jing-song li jiaqi shi yong-jie hao kai jiang michael yamin itzhak d goldberg prakash narayan | 2017 | World Journal of Gastroenterology2017，23，23： | 1 |
| 8 | Steady-state pharmacokinetics and pharmacodynamics of meropenem in hospitalized patients显示文摘 | Cheathams C Kays M B smith D W | 2008 | Pharmacotherapy2008，28，6： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员